Congenica: CASE STUDY

2025-06-24T16:46:17+01:0016 January 2024|

Based on pioneering research from the Wellcome Sanger Institute and the UK NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres, and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.

The Global Fight Against Malaria

2025-06-24T16:45:42+01:0014 January 2024|

Despite much progress that has been made to battle the disease, it remains a significant global healthcare challenge. By the 1970s, through public health measures such as the use of insecticides and anti-malarial drugs, the disease was virtually eliminated from the more affluent regions of the globe, but sadly it remains endemic in most of the tropical and subtropical regions of the world today, disproportionately affecting poor and vulnerable populations. It is found in more than 100 countries mainly in tropical regions of the world, including: large areas of Africa and Asia, Central and South America, Haiti and the Dominican Republic, parts of the Middle East and some Pacific islands. In regions where transmission remains high, it is often the leading cause of illness and death.

Kymab: CASE STUDY

2025-06-24T16:44:53+01:0012 January 2024|

Kymab was a therapeutic antibody company based in Cambridge, UK, developing novel solutions in drug and vaccine development. Using its unique technology with roots in the laboratories of the Wellcome Sanger Institute, the company developed broad diversity, high-quality human antibodies. Kymab's therapeutics were designed to modulate the immune system to overcome cancer immune tolerance and to treat autoimmune diseases.

COSMIC: CASE STUDY

2025-06-24T16:44:13+01:0010 January 2024|

COSMIC is an online catalogue of somatic mutations in cancer, a gold standard data resource of global impact in the field of cancer genomics. The database has utility for basic research into the mechanisms of cancer but is also relevant for pharmaceutical R&D activities in oncology as well as the development of products and services in cancer diagnosis and patient stratification.

From somatic mutations to Quotient

2024-07-05T10:10:12+01:0021 November 2023|

We spoke to Dr Iñigo Martincorena, group leader at the Wellcome Sanger Institute and academic co-founder of Quotient Therapeutics. Quotient is a new company leveraging Sanger Institute research to innovate the way drugs are discovered.

Mosaic’s becoming

2024-07-05T10:46:37+01:0012 September 2023|

The Sanger Institute is committed to innovative science at scale, but we need partners and investors to transfer this science into the clinic. Mariya Chhatriwala, Business Development Manager, gives us her insights on how the Sanger Institute’s fifth spin-out company came to be.

Accidental Entrepreneur

2024-07-05T10:42:40+01:0023 March 2023|

In this third part of our innovator blog series, we spoke to Matt Hurles, Head of the Human Genetics programme and incoming Director of the Wellcome Sanger Institute. Matt defines himself as an accidental entrepreneur, even though he spearheads a number of innovative initiatives that showcase his motivation to ultimately bring benefits to patients.

A passion for problem solving

2024-07-05T10:43:16+01:009 February 2023|

As part of our innovator blog series, we spoke to Qianxin Wu who works jointly in our Cellular Genetics programme and our Cellular and Gene Editing R&D team. Qianxin is at the forefront of innovation, working on CRISPR, genome editing and single-cell technologies.